Core Viewpoint - Investors should focus on "quality dividends" rather than merely seeking "high dividends," emphasizing a bottom-up stock selection strategy that considers operational resilience, capital allocation discipline, and sustainability of shareholder return policies [1] Group 1: Investment Strategy - Fidelity International emphasizes the importance of identifying high-quality companies in sectors such as information services, finance, utilities, consumer staples, and insurance, which exhibit strong cash flow and stable dividend records [1] - The use of active management strategies, such as covered call options, can enhance portfolio cash flow without significantly sacrificing capital appreciation potential [1] Group 2: Market Outlook - The global stock market is expected to experience volatility through 2025, influenced by geopolitical and trade policy challenges, prompting investors to adjust their confidence and asset allocation [1] - Despite market turbulence, recent data indicates significant capital inflows into global stock markets, although there are signs of slowing capital rotation in North American markets, suggesting a shift towards diversified market allocations [1] Group 3: Geographic Diversification - Diversification across regions, including the U.S., Europe, and Asia, is crucial for enhancing portfolio resilience against market fluctuations and policy changes [2] - U.S. companies face pressure from tariffs and policy disruptions, leading Fidelity to focus less on U.S. stocks and more on service industries that are less directly impacted [2] - European companies with a global revenue base and strong dividend policies present good opportunities for risk diversification and return generation, despite a conservative economic outlook [2] Group 4: Quality and Dividend Growth - High-quality index investments demonstrate higher efficiency and lower volatility, with approximately 40% of total global stock market returns derived from dividends [3] - Dividend growth potential reflects operational quality, allowing investors to participate in capital market growth in a more stable manner [3] - Continuous dividend growth is a key factor, as it not only provides cash flow but also constitutes a significant part of long-term returns [2][3]

Group 1: Company Overview - Steady Medical Group, founded in 1991, has evolved into a health enterprise focusing on medical and consumer sectors, listed on the Shenzhen Stock Exchange in 2020 [13] - The company aims to "protect health, care for life, and protect the environment" with its main brands being "Winner Medical" and "Purcotton" [13] Group 2: Annual Performance Review - In 2024, the company achieved a total revenue of 89.8 billion CNY, a 9.7% increase from 2023's 81.9 billion CNY [18] - Excluding infection protection product revenue, the adjusted revenue was 86.2 billion CNY, reflecting an 18.6% year-on-year growth [18] - The revenue structure for 2024 was 43% from medical consumables and 56% from consumer products [18] Group 3: Profitability - The net profit attributable to shareholders reached 7.0 billion CNY, a 19.8% increase compared to 2023 [21] - The net profit margin improved to 7.7%, up 0.7 percentage points from the previous year [21] - The gross profit margin for 2024 was 47.3%, indicating a stable profitability trend [20] Group 4: Asset Quality and R&D Investment - Total assets at the end of 2024 were 184 billion CNY, a 7.5% increase from the previous year [26] - The asset-liability ratio stood at 35.4%, maintaining a low level [26] - The company emphasized R&D, with a steady increase in the number of patents and medical product registrations [26] Group 5: Shareholder Returns - The proposed cash dividend for 2024 is 3.8 billion CNY, representing 54% of the net profit [30] - Cumulative cash dividends since listing amount to 26.1 billion CNY, accounting for 93% of the net proceeds from the IPO [30] Group 6: Medical Consumables Business - The medical segment generated 39.1 billion CNY in revenue for 2024, showing resilience despite a high base from infection protection products [34] - Excluding infection protection, the medical consumables revenue was 35.5 billion CNY, a 20.4% increase year-on-year [34] - Core categories such as high-end dressings and surgical consumables saw revenue growth exceeding 30% [34] Group 7: Consumer Products Business - The consumer segment, led by Purcotton, achieved 49.9 billion CNY in revenue, a 17.1% increase from 2023 [43] - Online sales contributed 62% of the revenue, while offline stores accounted for 30% [46] - The company added 92 new offline stores in 2024, bringing the total to 487 [46] Group 8: Q1 2025 Performance Overview - In Q1 2025, total revenue reached 26.1 billion CNY, a 36.5% increase year-on-year [53] - The medical business revenue for Q1 2025 was 12.5 billion CNY, up 46.3% [54] - The consumer business generated 13.4 billion CNY, reflecting a 28.8% growth [54]